We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+22.56%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$552M
AUM Growth
+$7.32M
Cap. Flow
-$37.8M
Cap. Flow %
-6.85%
Top 10 Hldgs %
77.03%
Holding
24
New
4
Increased
10
Reduced
6
Closed
3

Top Buys

1
CADL icon
Candel Therapeutics
CADL
+$15.8M
2
IRON icon
Disc Medicine
IRON
+$10.5M
3
IVVD icon
Invivyd
IVVD
+$5.9M
4
IMMX icon
Immix Biopharma
IMMX
+$5.1M
5
ZURA icon
Zura Bio
ZURA
+$4.47M

Top Sells

1
COGT icon
Cogent Biosciences
COGT
+$21.8M
2
OCUL icon
Ocular Therapeutix
OCUL
+$18.3M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$14.9M
4
DYN icon
Dyne Therapeutics
DYN
+$14.2M
5
ABVX
Abivax
ABVX
+$12.6M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALMS
1
Alumis Inc
ALMS
$3.65B
$70.5M 12.77%
3,202,075
+66,122
+2% +$1.65M
AMLX icon
2
Amylyx Pharmaceuticals
AMLX
$1.97B
$60.5M 10.95%
4,349,885
-146,602
-3% -$2.06M
ABVX
3
Abivax
ABVX
$11.9B
$60.4M 10.94%
542,696
-106,483
-16% -$12.6M
PCVX icon
4
Vaxcyte
PCVX
$8.12B
$47.9M 8.68%
824,532
+25,592
+3% +$1.39M
PHVS icon
5
Pharvaris
PHVS
$2.44B
$33.9M 6.15%
1,201,402
+61,369
+5% +$1.64M
IMMX icon
6
Immix Biopharma
IMMX
$730M
$33.6M 6.09%
3,693,585
+694,416
+23% +$5.1M
CELC icon
7
Celcuity
CELC
$4.31B
$32.2M 5.83%
281,904
-35,191
-11% -$3.84M
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$15.5B
$30.8M 5.58%
162,961
-85,109
-34% -$14.9M
IRON icon
9
Disc Medicine
IRON
$2.91B
$28.8M 5.21%
449,926
+151,497
+51% +$10.5M
XFOR icon
10
X4 Pharmaceuticals
XFOR
$360M
$26.7M 4.83%
6,456,646
+656,116
+11% +$2.46M
COGT icon
11
Cogent Biosciences
COGT
$6.68B
$24.1M 4.37%
626,635
-590,429
-49% -$21.8M
MNPR icon
12
Monopar Therapeutics
MNPR
$744M
$18.9M 3.43%
345,626
+19,925
+6% +$1.2M
DYN icon
13
Dyne Therapeutics
DYN
$3.92B
$17.5M 3.17%
966,609
-822,007
-46% -$14.2M
IVVD icon
14
Invivyd
IVVD
$219M
$14.2M 2.58%
10,949,084
+3,213,698
+42% +$5.9M
CADL icon
15
Candel Therapeutics
CADL
$746M
$14.2M 2.57%
+2,896,588
New +$15.8M
OCS icon
16
Oculis Holding
OCS
$736M
$13.7M 2.49%
516,761
– –
OVID icon
17
Ovid Therapeutics
OVID
$455M
$9.25M 1.68%
4,166,666
+1,666,666
+67% +$2.98M
IKT icon
18
Inhibikase Therapeutics
IKT
$331M
$6.49M 1.18%
3,863,445
+6,646
+0.2% +$11.8K
ZURA icon
19
Zura Bio
ZURA
$518M
$4.4M 0.8%
+739,960
New +$4.47M
ANRO icon
20
Alto Neuroscience
ANRO
$1.07B
$2M 0.36%
+88,999
New +$1.65M
MSLE
21
Satellos Bioscience
MSLE
$186M
$1.97M 0.36%
+350,000
New +$3.44M
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-282,692
Closed -$7.07M
IVA
23
Inventiva
IVA
$1.09B
– –
-283,166
Closed -$1.32M
OCUL icon
24
Ocular Therapeutix
OCUL
$1.96B
– –
-1,504,880
Closed -$18.3M

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
FWM
FFT Wealth Management Philadelphia, Pennsylvania $552M AUM 16.82% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return

Saturn V Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Saturn V Capital Management held 24 positions worth $552M, up 1.3% from $545M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Saturn V Capital Management withdrew a net $37.8M in Q1 2026, closing 3 positions and reducing 6 holdings. Its most notable exit was Ocular Therapeutix, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Saturn V Capital Management opened a new position in Candel Therapeutics worth $14.2M.

  • Saturn V Capital Management's largest Q1 2026 buy was Candel Therapeutics: 2,896,588 shares worth $14.2M.
  • Saturn V Capital Management added most to Disc Medicine in Q1 2026, an estimated $10.5M increase.
  • Saturn V Capital Management's biggest Q1 2026 reduction was Cogent Biosciences, cutting an estimated $21.8M.
  • Saturn V Capital Management fully exited Ocular Therapeutix in Q1 2026, selling an estimated $18.3M.
  • Saturn V Capital Management's ten largest holdings make up 77% of its $552M portfolio in Q1 2026.
  • Saturn V Capital Management opened 4 new positions and closed 3 in Q1 2026.
  • Saturn V Capital Management's portfolio value rose 1.3% quarter-over-quarter to $552M.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.